Head-to-head evidence
PB-201 vs SY-004
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
PB-201
Developed by PegBio
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
SY-004
Developed by Suzhou Yabao Pharmaceutical
NCT04217291 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 200 participants, but its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. Because the registry does not report whether the primary comparison was favorable or statistically significant, the evidence is limited to a moderate grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PB-201's landscape · SY-004's landscape